Director/PDMR Share Dealings

    October 28, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
    it was notified today that deferred American Depositary Shares ("ADSs") granted
    to Phil Vickers, a Person Discharging Managerial Responsibilities, were
    automatically released today in accordance with the terms of a deferred share
    award granted on November 11, 2013. One ADS is equal to three Ordinary shares
    of 5 pence each in the Company.

    The number of ADSs released and the number that lapsed are as follows:

    ADSs Released(1)        ADSs Lapsed(2)              
                                                        
    493                     442                         

    (1) In accordance with the terms of the deferred share award, the vested
    deferred ADSs were increased by an amount equivalent, at the date of vesting,
    to the value of dividends paid by the Company in respect of the deferred ADSs
    from the date of grant to the date of vesting.

    (2) The number of ADSs lapsed is equivalent in value to Mr. Vickers' tax
    liability resulting from the release of the deferred ADSs.

    No amount was payable by Mr. Vickers in respect of the release of the deferred
    ADSs.

    This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
    of the Disclosure Rules and Transparency Rules.

    Oliver Strawbridge
    Senior Assistant Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Matthew Osborne                     mattosborne@shire.com  +1 781 482 9502   
                                                                                 
    Sarah Elton-Farr                    seltonfarr@shire.com   +44 1256 894157   

    NOTES TO EDITORS

    Shire enables people with life-altering conditions to lead better lives.

    Our strategy is to focus on developing and marketing innovative specialty
    medicines to meet significant unmet patient needs.

    We focus on providing treatments in Rare Diseases, Neuroscience,
    Gastrointestinal and Internal Medicine and we are developing treatments for
    symptomatic conditions treated by specialist physicians in other targeted
    therapeutic areas, such as Ophthalmics.

    http://www.shire.com/